Canaccord Genuity Group Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price

Guardant Health (NASDAQ:GH) had its target price increased by equities research analysts at Canaccord Genuity Group from $125.00 to $135.00 in a report released on Friday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 26.90% from the company’s previous close.

A number of other research firms have also recently weighed in on GH. UBS Group restated a “buy” rating and set a $175.00 target price on shares of Guardant Health in a research note on Friday, January 30th. Mizuho set a $135.00 target price on shares of Guardant Health in a report on Friday, January 9th. BTIG Research increased their price target on shares of Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a report on Friday, December 12th. Wells Fargo & Company boosted their price objective on Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Robert W. Baird began coverage on Guardant Health in a research note on Tuesday. They issued an “outperform” rating and a $120.00 price objective for the company. Twenty-two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.59.

Guardant Health Stock Performance

NASDAQ GH opened at $106.38 on Friday. The business’s fifty day moving average is $106.67 and its 200 day moving average is $85.53. Guardant Health has a fifty-two week low of $34.88 and a fifty-two week high of $120.74. The company has a market capitalization of $13.41 billion, a PE ratio of -33.14 and a beta of 1.63.

Insiders Place Their Bets

In other Guardant Health news, insider Terilyn J. Monroe sold 8,571 shares of Guardant Health stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $114.09, for a total value of $977,865.39. Following the transaction, the insider owned 20,990 shares in the company, valued at $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.00, for a total transaction of $131,250.00. Following the completion of the sale, the director owned 797 shares in the company, valued at $83,685. This represents a 61.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 434,511 shares of company stock worth $45,580,887. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mcguire Capital Advisors Inc. purchased a new position in Guardant Health during the 4th quarter worth $155,000. Hamilton Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $3,859,000. Mercer Global Advisors Inc. ADV increased its stake in Guardant Health by 12.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,357 shares of the company’s stock valued at $445,000 after purchasing an additional 490 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Guardant Health by 57.6% during the fourth quarter. Mackenzie Financial Corp now owns 36,023 shares of the company’s stock worth $3,617,000 after buying an additional 13,172 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Q4 revenue beat and strong top-line growth — Guardant reported revenue of $281.3M (+39% YoY), driven by oncology test volumes, which suggests healthy demand and execution on growth levers. Business Wire Q4 results
• Positive Sentiment: FY-2026 revenue guidance raised to about $1.3B, above the ~$1.2B consensus, giving visible top‑line momentum for next year (EPS guidance was not meaningfully updated in the releases). Guidance press release
• Neutral Sentiment: Robert W. Baird initiated research coverage on Guardant, which can increase analyst attention and liquidity; the initiation may influence sentiment depending on the published rating and price target. American Banking News
• Neutral Sentiment: Full Q4 earnings call transcript is available for management commentary on growth drivers, margin trajectory, and product cadence — useful for parsing the outlook and execution details behind the guidance. Earnings call transcript
• Neutral Sentiment: Analyst/metrics coverage pieces (Zacks) provide deeper look at which line items out- or underperformed versus Street estimates. Zacks metrics analysis
• Negative Sentiment: EPS missed expectations: GAAP loss of $0.50/sh vs. consensus -$0.43, continuing the company’s negative earnings trend and keeping profitability concerns front-and-center for investors. Zacks Q4 loss report

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.